Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

Shelley Wood

November 29, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Conference News SCCT 2019

Retrospective Study Validates CAC-DRS Score for Predicting Mortality

Yael L. Maxwell

July 23, 2019

News Daily News

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Michael O'Riordan

July 22, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News SCCT 2019

Sex-Specific ‘Inventory’ Needed to Spot Key CVD Risk Factors in Women

Yael L. Maxwell

July 12, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

Advertisement

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

TCTMD’s Top 10 Most Popular Stories for November 2019

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Retrospective Study Validates CAC-DRS Score for Predicting Mortality

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Sex-Specific ‘Inventory’ Needed to Spot Key CVD Risk Factors in Women

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content